<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="183839">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700947</url>
  </required_header>
  <id_info>
    <org_study_id>2007H0120</org_study_id>
    <secondary_id>AHA-0335098N</secondary_id>
    <nct_id>NCT00700947</nct_id>
  </id_info>
  <brief_title>Using Beta Blockers to Treat Mitral Regurgitation</brief_title>
  <acronym>REGURG</acronym>
  <official_title>Beta-Blockade in Chronic Mitral Regurgitation: Moving From the Laboratory Experiment to Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study tests whether a beta-blocker drug will benefit patients with
      chronic mitral regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study tests whether Toprol xl, a beta-blocker drug, will benefit
      patients with chronic mitral regurgitation after mitral valve surgery and to investigation
      effects of chronic mitral regurgitation on heart size, heart function, exercise capacity and
      clinical symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the impact of chronic mitral regurgitation (MR) on neurohormonal activation, left ventricular remodeling, function and reserve in patients with or without surgery. Determine the effect of beta-blockade previously mentioned markers of MR.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test new noninvasive methods to assess global and regional myocardial contractility in chronic MR, correlating the results with biochemical markers.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Heart Disease</condition>
  <condition>Mitral Regurgitation</condition>
  <condition>Heart Valve Disease</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have may or may not of been surgically treated for mitral regurgitation that start Beta-Blocker therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who have been surgically treated for mitral regurgitation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Health Control with no remarkable past medical history and not currently taking any medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-blocker therapy (TOPROL-XLÂ® )</intervention_name>
    <description>Patients who have been surgically treated for mitral regurgitation that start Beta-Blocker therapy.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Mitral Regurgitation

        Exclusion Criteria:

          -  Left ventricle ejection fraction of &lt;55% pre and post operation

          -  Pregnancy or Lactation

          -  Secondary mitral regurgitation due to coronary artery disease, cardiomyopathy,
             uncontrolled hypertension, or severe aortic stenosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Pu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <lastchanged_date>October 15, 2009</lastchanged_date>
  <firstreceived_date>December 26, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Min Pu, MD, PhD</name_title>
    <organization>The Ohio State University</organization>
  </responsible_party>
  <keyword>Heart Disease</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Heart Valve Disease</keyword>
  <keyword>Mitral Valve Insufficiency</keyword>
  <keyword>Heart Surgery</keyword>
  <keyword>Heart Valve Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
